» Articles » PMID: 30310512

Improved Survival in Ovarian Cancer, with Widening Survival Gaps of Races and Socioeconomic Status: a Period Analysis, 1983-2012

Overview
Journal J Cancer
Specialty Oncology
Date 2018 Oct 13
PMID 30310512
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is the first leading cause of cancer-related deaths among gynecologic malignancies, and the 7th most common female cancer worldwide. However, previous studies on changes in the long-term survival of ovarian cancer were limited. Our data were extracted from Surveillance, Epidemiology, and End Results (SEER) registries to assess the incidence and relative survival changes of patients with ovarian cancer during 1983-2012. Patients with ovarian cancer were stratified by age, race, and socioeconomic status (SES). Cox regression analysis and Spearman rank correlation analysis were performed by STATA 12 software. The overall incidence of ovarian cancer per 100,000 decreased from 13.7 to 12.4 to 10.8 over three decades with peak incidence occurring in the 70+ age group at 47.6, 45.7 and 40.2 in each respective decade. Median survival improved from 34 months to 46 months to 52 months over three decades, with the 5-year relative survival rate (RSR) increasing from 39.3% to 43.4% to 45.4% ( < 0.0001). However, Whites showed higher median survival (34 months) than Blacks (27 months) in the first decade, and the survival difference significantly increased to 16 months in the third decade. Additionally, the median survival difference between the low-poverty group and high poverty group increased from 4 months to 12 months in the three decades. This study demonstrated the decreasing incidence of ovarian cancer with an observed improvement in relative survival over three decades in a large sample. However, the survival gaps among races and SESs significantly widened over the three decades.

Citing Articles

Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study.

Lahelma M, Rauhamaa H, Leskela R, Isomeri O, Idanpaan-Heikkila J, Kakela S Acta Oncol. 2024; 63:763-771.

PMID: 39415562 PMC: 11495122. DOI: 10.2340/1651-226X.2024.40324.


Geographically weighted accelerated failure time model for spatial survival data: application to ovarian cancer survival data in New Jersey.

Cai J, Li Y, Hu W, Jing H, Mi B, Pei L BMC Med Res Methodol. 2024; 24(1):239.

PMID: 39407106 PMC: 11476607. DOI: 10.1186/s12874-024-02346-8.


Stage IV ovarian cancer prognosis nomogram and analysis of racial differences: A study based on the SEER database.

Wu G, Chen J, Niu P, Huang X, Chen Y, Zhang J Heliyon. 2024; 10(16):e36549.

PMID: 39262992 PMC: 11388394. DOI: 10.1016/j.heliyon.2024.e36549.


Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population.

Olaoye T, - A, Boyle W, Williams A, Ganesan R, Subba K Int J Gynecol Cancer. 2024; 34(9):1399-1407.

PMID: 38862154 PMC: 11420762. DOI: 10.1136/ijgc-2024-005332.


Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.

Wilkinson A, Chen R, Coleborn E, Neilson T, Le K, Bhavsar C Cancer Immunol Immunother. 2024; 73(5):80.

PMID: 38554167 PMC: 10981620. DOI: 10.1007/s00262-024-03674-w.


References
1.
Barnholtz-Sloan J, Schwartz A, Qureshi F, Jacques S, Malone J, Munkarah A . Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003; 189(4):1120-7. DOI: 10.1067/s0002-9378(03)00579-9. View

2.
Mahdi H, Kumar S, Munkarah A, Abdalamir M, Doherty M, Swensen R . Prognostic impact of marital status on survival of women with epithelial ovarian cancer. Psychooncology. 2011; 22(1):83-8. DOI: 10.1002/pon.2058. View

3.
Krieger N, Chen J, Waterman P, Rehkopf D, Subramanian S . Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures--the public health disparities geocoding project. Am J Public Health. 2003; 93(10):1655-71. PMC: 1448030. DOI: 10.2105/ajph.93.10.1655. View

4.
Sakhuja S, Yun H, Pisu M, Akinyemiju T . Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites. J Ovarian Res. 2017; 10(1):57. PMC: 5568254. DOI: 10.1186/s13048-017-0352-1. View

5.
Dinkelspiel H, Tergas A, Zimmerman L, Burke W, Hou J, Chen L . Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. Gynecol Oncol. 2015; 137(2):203-9. PMC: 4426072. DOI: 10.1016/j.ygyno.2015.02.013. View